Sandoz, >98% (HPLC), powder
Application
Sandoz 58-035 was used to induce simultaneous activation of unfolded protein response (UPR) and pattern recognition receptors (PRRs) in mouse peritoneal macrophages.3
Biochem/physiol Actions
Sandoz 58-035 inhibits the accumulation of cholesteryl esters and inhibits the esterification of cholesterol by 95% in arterial smooth muscle cells in culture.1 It does not affect the triglyceride metabolism by the gut.2
Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
No detailed specifications are available for this product.
There are no downloads for this product.